Your browser doesn't support javascript.
loading
New frontiers in pediatric Allo-SCT.
Talano, J M; Pulsipher, M A; Symons, H J; Militano, O; Shereck, E B; Giller, R H; Hancock, L; Morris, E; Cairo, M S.
Afiliação
  • Talano JM; Department of Pediatrics, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Pulsipher MA; Department of Pediatrics, University of Utah, Salt Lake City, UT, USA.
  • Symons HJ; Department of Oncology, Johns Hopkins Hospital, Baltimore, MD, USA.
  • Militano O; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
  • Shereck EB; Oregon Health and Science University, Portland, OR, USA.
  • Giller RH; Children's Hospital Colorado, Aurora, CO, USA.
  • Hancock L; Pediatric Blood and Marrow Transplant Consortium, Monrovia, CA, USA.
  • Morris E; Department of Pediatrics, New York Medical College, Valhalla, NY, USA.
  • Cairo MS; 1] Department of Pediatrics, New York Medical College, Valhalla, NY, USA [2] Department of Medicine, New York Medical College, Valhalla, NY, USA [3] Department of Pathology, New York Medical College, Valhalla, NY, USA [4] Department of Microbiology and Immunology, New York Medical College, Valhalla,
Bone Marrow Transplant ; 49(9): 1139-45, 2014 Sep.
Article em En | MEDLINE | ID: mdl-24820213
ABSTRACT
The inaugural meeting of 'New Frontiers in Pediatric Allogeneic Stem Cell Transplantation' organized by the Pediatric Blood and Transplant Consortium (PBMTC) was held at the American Society of Pediatric Hematology and Oncology Annual Meeting. This meeting provided an international platform for physicians and investigators active in the research and utilization of pediatric Allo-SCT in children and adolescents with malignant and non-malignant disease (NMD), to share information and develop future collaborative strategies. The primary objectives of the conference included (1) to present advances in Allo-SCT in pediatric ALL and novel pre and post-transplant immunotherapy; (2) to highlight new strategies in alternative allogeneic stem cell donor sources for children and adolescents with non-malignant hematological disorders; (3) to discuss timing of immune reconstitution after Allo-SCT and methods of facilitating more rapid recovery of immunity; (4) to identify strategies of utilizing Allo-SCT in pediatric myeloproliferative disorders; (5) to develop diagnostic and therapeutic approaches to hematological complications post pediatric Allo-SCT; (6) to enhance the understanding of new novel cellular therapeutic approaches to pediatric malignant and non-malignant hematological disorders; and (7) to discuss optimizing drug therapy in pediatric recipients of Allo-SCT. This paper will provide a brief overview of the conference.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Idioma: En Ano de publicação: 2014 Tipo de documento: Article